{"entity":{"id":"nct07354711","kind":"trial","name":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of 3H-10000 in gastric & gastro-oesophageal junction cancer, run by 3H Pharmaceuticals Co., Ltd., now recruiting.","summary":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07354711 by 3H Pharmaceuticals Co., Ltd., with 170 participants planned, started 2026-01-04 and due to reach its primary completion in 2028-01. Interventions recorded: 3H-10000.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07354711","url":"https://clinicaltrials.gov/study/NCT07354711"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07354711","phase":"1/2","setting":"A Phase I/II Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors","sponsor":"3H Pharmaceuticals Co., Ltd.","started":"2026-01-04","startedType":"actual","enrolled":170,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07354711/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}